The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

The US on Friday approved the first blood test for Alzheimer's, a move that can help patients begin treatment earlier with ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...